Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP757116.RArQPsuB50q2-v3hDV4lMqYA-PcpsO9GCQymqhPF46SqU130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP757116.RArQPsuB50q2-v3hDV4lMqYA-PcpsO9GCQymqhPF46SqU130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP757116.RArQPsuB50q2-v3hDV4lMqYA-PcpsO9GCQymqhPF46SqU130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP757116.RArQPsuB50q2-v3hDV4lMqYA-PcpsO9GCQymqhPF46SqU130_provenance.
- befree-2016 importedOn "2016-02-19" NP757116.RArQPsuB50q2-v3hDV4lMqYA-PcpsO9GCQymqhPF46SqU130_provenance.
- NP757116.RArQPsuB50q2-v3hDV4lMqYA-PcpsO9GCQymqhPF46SqU130_assertion wasGeneratedBy ECO_0000203 NP757116.RArQPsuB50q2-v3hDV4lMqYA-PcpsO9GCQymqhPF46SqU130_provenance.
- NP757116.RArQPsuB50q2-v3hDV4lMqYA-PcpsO9GCQymqhPF46SqU130_assertion wasDerivedFrom befree-2016 NP757116.RArQPsuB50q2-v3hDV4lMqYA-PcpsO9GCQymqhPF46SqU130_provenance.
- NP757116.RArQPsuB50q2-v3hDV4lMqYA-PcpsO9GCQymqhPF46SqU130_assertion SIO_000772 19673887 NP757116.RArQPsuB50q2-v3hDV4lMqYA-PcpsO9GCQymqhPF46SqU130_provenance.
- NP757116.RArQPsuB50q2-v3hDV4lMqYA-PcpsO9GCQymqhPF46SqU130_assertion evidence source_evidence_literature NP757116.RArQPsuB50q2-v3hDV4lMqYA-PcpsO9GCQymqhPF46SqU130_provenance.
- NP757116.RArQPsuB50q2-v3hDV4lMqYA-PcpsO9GCQymqhPF46SqU130_assertion description "[Clinical efficacy of gefitinib (ZD1839, Iressa), which is an inhibitor specific for epidermal growth factor (EGF) receptor tyrosine kinase, has been shown in non-small-cell lung carcinoma patients with EGF receptor mutations, so these mutations are useful marker(s) to find a responder for the drug.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP757116.RArQPsuB50q2-v3hDV4lMqYA-PcpsO9GCQymqhPF46SqU130_provenance.